ArticleWiener klinische Wochenschrift2020
Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement.
Article in Wiener klinische Wochenschrift, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review.ESC heart failure · 2022Pooled it
- A Potential Approach to Bridge the Diagnostic Gap and Propose a Referral Pathway for Suspected ATTR-CA Based on Incidental Cardiac Uptake inDiagnostics (Basel, Switzerland) · 2026Article
- The prospective Austrian hypertrophic cardiomyopathy registry - design, methods and results of the run-in period.Heart failure reviews · 2026Article
- CMR-derived skeletal muscle T1 time and extracellular volume as novel diagnostic markers for cardiac amyloidosis.European journal of clinical investigation · 2026Article
- Cardiac amyloidosis: From diagnosis to therapeutics breakthroughs.World journal of experimental medicine · 2026Review
- Trends and disparities in amyloidosis and cardiovascular disease mortality: a population-based retrospective study in the United States (1999-2020).BMC cardiovascular disorders · 2026Article
- An Integrative Review of the Cardiovascular Disease Spectrum: Integrating Multi-Omics and Artificial Intelligence for Precision Cardiology.Diseases (Basel, Switzerland) · 2026Review
- On the crossroads of interdisciplinary medicine in amyloidosis - study protocol for a single-center interdisciplinary registry study.PloS one · 2026Article
- Serial extracellular volume quantification using cardiac magnetic resonance imaging in transthyretin amyloidosis patients treated with tafamidis.European radiology · 2026Article
- Article
- Advances in imaging-based diagnosis, prognosis, and response assessment in cardiac amyloidosis: a comprehensive multimodality review.Annals of nuclear medicine · 2025Review
- Prevalence of Atrial Fibrillation and Intervention Therapy in Cardiac Amyloidosis.Reviews in cardiovascular medicine · 2025Review
- Integrated specialty care for amyloidosis: a scoping review using the Consolidated Framework for Implementation Research.BMC health services research · 2025Article
- The Role of Artificial Intelligence in the Detection of Cardiac Amyloidosis: A Systematic Review.Cureus · 2025Review
- Diagnostic challenges in cardiac amyloidosis: a case report of negative initial endomyocardial biopsy.International journal of physiology, pathophysiology and pharmacology · 2025Article
- Unexplained cardiac hypertrophy as a clue to plasma cell tumour: a case study.American journal of translational research · 2025Article
- Article
- Review
- Examining the Difficulties in Identifying and Handling Cardiac Amyloidosis; Acquiring Important Knowledge and Robust Treatment Methods.Cardiovascular & hematological disorders drug targets · 2024Review
- Myocardial structural and functional changes in cardiac amyloidosis: insights from a prospective observational patient registry.European heart journal. Cardiovascular Imaging · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 7 institutions in 1 country.
Funding
Abstract
The prevalence and significance of cardiac amyloidosis have been considerably underestimated in the past; however, the number of patients diagnosed with cardiac amyloidosis has increased significantly recently due to growing awareness of the disease, improved diagnostic capabilities and demographic trends. Specific therapies that improve patient prognosis have become available for certain types of cardiac amyloidosis. Thus, the earliest possible referral of patients with suspicion of cardiac amyloidosis to an experienced center is crucial to ensure rapid diagnosis, early initiation of treatment, and structured patient care. This requires intensive collaboration across several disciplines, and between resident physicians and specialized centers. The aim of this consensus statement is to provide guidance for the rapid and efficient diagnosis and treatment of light-chain amyloidosis and transthyretin amyloidosis, which are the most common forms of cardiac amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.